Intravitreal combination of Triamcinolone Acetonide and Bevacizumab seems to be effective in improving visual acuity and macular edema in patients with diabetic maculopathy.
Purpose To investigate the effect of intravitreal ketorolac tromethamine in chronic post‐operative cystoid macular edema.
Methods Six patients diagnosed with chronic post‐operative CME non responsive in conventional therapies, were enrolled. 2 patients received 2 intravitreal injections of 300 μg (0.05ml) of ketorolac tromethamine (Toradol) with a 3‐week interval, three patients received 4 consecutive injections of 500 μg (0.05ml) weekly and 3 patients received 4 consecutive injections of 500 μg (0.05ml) daily. Patients were followed by means of biomicroscopy, fluorescein angiography and optical coherent tomography. Follow‐up lasted up to six months.
Results No adverse effect was noticed in any of the patients. A trend for visual acuity improvement and macular edema regression was noticed after initiation of the therapy. A rebound of the edema happened usually a week after the last injection. In the long follow‐up regression of the macular edema was noticed in three out of six patients.
Conclusion This pilot study indicates a possible role of intravitreal injection of ketorolac tromethamine in patients with chronic postoperative cystoid macular edema. Further research is warranted in order to obtain conclusive results concerning doses and timing of injections.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.